Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wayne Nelson

Vascular Surgery Bend, OR Medical Doctor

NPI 1992909766 CMS profile 363200

1550 Ne 27Th St Ste 100, Bend, OR 97701

Open in the dashboard

General payments

$69,219

537 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$8,473 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Wayne Nelson of Bend, OR is reported in the CMS Open Payments database as having received $69,219 across 537 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $8,473 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,635 41
2024 General $4,541 83
2023 General $14,302 75
2022 General $19,525 84
2021 General $11,195 90
2020 General $8,176 64
2019 General $8,846 100

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wayne Nelson
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Wayne Nelson were reported at $2,635. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Wayne Nelson Vascular Surgery median Middle half National median
2019 $8,846 $796 $226–$2,363 $163
2020 $8,176 $348 $118–$1,110 $114
2021 $11,195 $471 $158–$1,421 $132
2022 $19,525 $725 $222–$2,183 $149
2023 $14,302 $836 $257–$2,440 $160
2024 $4,541 $909 $252–$2,619 $164
2025 $2,635 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Cook Incorporated $15,879 11 payments
  2. Janssen Pharmaceuticals, Inc $13,275 42 payments
  3. Silk Road Medical, Inc. $9,490 87 payments
  4. Shockwave Medical, Inc $7,190 15 payments
  5. W. L. Gore & Associates, Inc. $3,556 48 payments
  6. AngioDynamics, Inc. $3,328 4 payments
  7. Boston Scientific Corporation $2,980 88 payments
  8. Cook Medical LLC $2,736 66 payments
  9. Penumbra, Inc. $1,759 16 payments
  10. Medtronic Vascular, Inc. $1,636 23 payments
  11. Other $7,391 137 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $23,234 498 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $21,360 14 payments
  3. Consulting Fee $6,900 4 payments
  4. Compensation for serving as faculty or as a speaker for a medical education program $6,600 1 payment
  5. Travel and Lodging $4,905 15 payments
  6. Education $3,200 3 payments
  7. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $3,020 2 payments
Products named General payments · program years 2019–2025
  1. XARELTO $13,275 42 payments
  2. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $7,062 12 payments
  3. ENROUTE Transcarotid Stent $5,473 57 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $5,473 57 payments
  5. COOK $5,243 11 payments
  6. ENROUTE 0.014 Guidewire $4,017 30 payments
  7. ENROUTE Transcarotid Stent System $4,017 30 payments
  8. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $4,017 30 payments
  9. ENHANCE Transcarotid Peripheral Access Kit $4,017 30 payments
  10. ZENITH ALPHA $3,473 4 payments
  11. Other $33,510 448 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

549

Median for Vascular Surgery: 122

Drug cost

$117,498

Median for Vascular Surgery: $14,135

Branded share of claims

91.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 58 $59,310
Xarelto Rivaroxaban Brand 36 $50,389
Clopidogrel Clopidogrel Bisulfate Brand 406 $6,885
Gabapentin Generic 15 $362
Atorvastatin Calcium Generic 21 $277
Rosuvastatin Calcium Generic 13 $275

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$900,297

Of which drugs: $488

Medicare patients

1,033

Average age 77

Services billed

7,709

456 women, 577 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 49%
Arthritis 46%
Diabetes 33%
Chronic kidney disease 29%
COPD 27%
Heart failure 26%
Atrial fibrillation 25%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 66 4,760 $488

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

537 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record